Free tool
FAERS Monitor: Yuvezzi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220142 or its brand name (Yuvezzi, Brimonidine Tartrate, Carbachol). Reports on generic versions are filed under their own applications.
Reports
173
Serious
6
3% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache83
- drug ineffective31
- vision blurred27
- eye pain23
- eye irritation21
- nausea19
- visual impairment19
- dizziness16
- migraine13
- ocular hyperaemia9
- miosis5
- ocular discomfort5
- therapeutic response shortened5
- vitreous detachment5
- myopia4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2026 | 173 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,986 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vitreous detachmentSignal | 5 | 281.2 | 118.4 | 1,127 |
| myopiaSignal | 4 | 204.6 | 77.6 | 619 |
| miosisSignal | 5 | 75.8 | 31.9 | 298 |
| ocular discomfortSignal | 5 | 54.2 | 22.8 | 210 |
| eye painSignal | 23 | 49.6 | 33.9 | 1,049 |
| eye irritationSignal | 21 | 44.4 | 29.7 | 849 |
| vision blurredSignal | 27 | 23.9 | 16.9 | 574 |
| ocular hyperaemiaSignal | 9 | 23.1 | 12.2 | 169 |
| visual impairmentSignal | 19 | 18.6 | 12.2 | 302 |
| therapeutic response shortenedSignal | 5 | 18.3 | 7.7 | 66 |
| migraineSignal | 13 | 16.6 | 9.8 | 176 |
| headacheSignal | 83 | 16.1 | 13.8 | 1,196 |
| dizzinessSignal | 16 | 3.9 | 2.4 | 32 |
| nauseaSignal | 19 | 2.9 | 1.9 | 23 |
| drug ineffectiveSignal | 31 | 2.9 | 2.1 | 38 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.